Cargando…

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

Several cytokines and growth factors, as well as their downstream signalling pathways, are implicated in the pathogenesis of haematological and immune-mediated diseases. These mediators act through binding to their cognate receptor and activation of one or more of the four Janus family tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autor principal: Bertsias, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361188/
https://www.ncbi.nlm.nih.gov/pubmed/32676568
http://dx.doi.org/10.31138/mjr.31.1.105
_version_ 1783559357121691648
author Bertsias, George
author_facet Bertsias, George
author_sort Bertsias, George
collection PubMed
description Several cytokines and growth factors, as well as their downstream signalling pathways, are implicated in the pathogenesis of haematological and immune-mediated diseases. These mediators act through binding to their cognate receptor and activation of one or more of the four Janus family tyrosine kinases (JAKs). Gene knock-out studies together with evidence from patients carrying activating mutant forms of JAKs (eg, JAK2 V617F in myeloproliferative disorders) provided strong rationale for the development of JAK inhibitors. Based on encouraging preclinical data showing the capacity of JAK inhibitors to suppress the signalling from multiple cytokines, an extensive drug development program was set out, with the initial successful introduction of tofacitinib, baricitinib and ruxolitinib in various chronic rheumatic and myeloproliferative diseases, respectively. Importantly, advancements with the design of next-generation, hyper-selective JAK inhibitors hold promise for the better control of inflammation, while reducing the risk for harms, in an expanding spectrum of medical disorders.
format Online
Article
Text
id pubmed-7361188
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-73611882020-07-15 Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors Bertsias, George Mediterr J Rheumatol Review Several cytokines and growth factors, as well as their downstream signalling pathways, are implicated in the pathogenesis of haematological and immune-mediated diseases. These mediators act through binding to their cognate receptor and activation of one or more of the four Janus family tyrosine kinases (JAKs). Gene knock-out studies together with evidence from patients carrying activating mutant forms of JAKs (eg, JAK2 V617F in myeloproliferative disorders) provided strong rationale for the development of JAK inhibitors. Based on encouraging preclinical data showing the capacity of JAK inhibitors to suppress the signalling from multiple cytokines, an extensive drug development program was set out, with the initial successful introduction of tofacitinib, baricitinib and ruxolitinib in various chronic rheumatic and myeloproliferative diseases, respectively. Importantly, advancements with the design of next-generation, hyper-selective JAK inhibitors hold promise for the better control of inflammation, while reducing the risk for harms, in an expanding spectrum of medical disorders. The Mediterranean Journal of Rheumatology (MJR) 2020-05-25 /pmc/articles/PMC7361188/ /pubmed/32676568 http://dx.doi.org/10.31138/mjr.31.1.105 Text en © 2020 The Mediterranean Journal of Rheumatology (MJR) http://creativecommons.org/licenses/by/4.0/ This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Review
Bertsias, George
Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title_full Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title_fullStr Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title_full_unstemmed Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title_short Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
title_sort therapeutic targeting of jaks: from hematology to rheumatology and from the first to the second generation of jak inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361188/
https://www.ncbi.nlm.nih.gov/pubmed/32676568
http://dx.doi.org/10.31138/mjr.31.1.105
work_keys_str_mv AT bertsiasgeorge therapeutictargetingofjaksfromhematologytorheumatologyandfromthefirsttothesecondgenerationofjakinhibitors